Zezhong Tian

Dr. Zezhong Tian

Sun Yat-sen University, Guangzhou, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in eClinicalMedicine
Verified
Journal Article
Open access
YLYing Liang
Ying Liang
DZDan Zhao
Dan Zhao
QJQiuhua Ji
Qiuhua Ji
MLMeitong Liu
Meitong Liu
SDSuming Dai
Suming Dai
YYYan Yang
Yan Yang
Previous reviews reported that the effects of CoQ10 on glycemic control were inconsistent. There is no review exploring the optimal intake of CoQ10 for glycemic control. We aimed to investigate the efficacy of CoQ10 on glycemic control and evaluate the dose–response relationship via integrating the existing evidence from randomized control trials (RCTs). Databases (PubMed, Embase, and Cochrane Library) were searched to identify RCTs for investigating the efficacy of CoQ10 on fasting glucose, fasting insulin, HbA1c, and HOMA-IR up to March 12, 2022. We performed a meta-analysis on 40 RCTs of CoQ10. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated for net changes. Evidence certainty was assessed using GRADE. Dose-response relationships were evaluated using 1-stage restricted cubic spline regression model. The protocol was registered in PROSPERO (CRD42021252933). Forty studies (n = 2,424 participants) were included in this meta-analysis. CoQ10 significantly reduced fasting glucose (WMD: -5.22 [95% CI: -8.33, -2.11] mg/dl; P <0.001; I2=95.10%), fasting insulin (-1.32 [-2.06, -0.58] μIU/ml; P < 0.001; I2=78.86%), HbA1c (-0.12% [-0.23, -0.01]; P =0.04; I2=49.10%), and HOMA-IR (-0.69 [-1.00, -0.38]; P <0.001; I2=88.80%). The effect of CoQ10 on outcomes was greater in diabetes with lower heterogeneity. A “U” shape dose-response relationship curve revealed that 100-200 mg/day of CoQ10 largely decreased fasting glucose (χ2 = 12.08, Pnonlinearity =0.002), fasting insulin (χ2 = 9.73, Pnonlinearity =0.008), HbA1c (χ2 = 6.00, Pnonlinearity =0.049), HOMA-IR (χ2 = 25.89, Pnonlinearity <0.001). CoQ10 supplementation has beneficial effects on glycemic control, especially in diabetes, and 100-200 mg/day of CoQ10 could achieve the greatest benefit, which could provide a basis for the dietary guidelines of CoQ10 in patients with glycemic disorders. This work was supported by the National Natural Science Foundation of China (No. 82030098, 81872617 and 81730090), Shenzhen Science, Technology, and Innovation Commission (No. JCYJ20180307153228190), CNS Research Fund for DRI, and National innovation and entrepreneurship training program for undergraduate student (No. 202210558161).

13 July 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
SDSuming Dai
Suming Dai
ZTZezhong Tian
Zezhong Tian
DZDan Zhao
Dan Zhao
YLYing Liang
Ying Liang
MLMeitong Liu
Meitong Liu
YYYan Yang
Yan Yang
Evidence shows that exogenous CoQ10 supplementation may potentially attenuate oxidative stress status. However, its effective dose and evidence certainty require further evaluation in the general population via more updated randomized controlled trials (RCTs). Databases (PubMed, Embase and Cochrane Library) were searched up to 30 March 2022. Evidence certainty was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Thirty-four RCTs containing 2012 participants were included in this review. Pooled effects of significant increase in total antioxidant capacity (TAC) (standardized mean difference: 1.83, 95%CI: [1.07, 2.59], p < 0.001) and significant reduction in malondialdehyde (MDA) concentrations (−0.77, [−1.06, −0.47], p < 0.001) were shown after CoQ10 supplementation compared to placebo. However, we could not determine that there was a significant increase in circulating superoxide dismutase (SOD) levels yet (0.47, [0.00, 0.94], p = 0.05). Subgroup analyses implied that CoQ10 supplementation was more beneficial to people with coronary artery disease or type 2 diabetes. Additionally, taking 100–150 mg/day CoQ10 supplement had better benefits for the levels of TAC, MDA and SOD (all p < 0.01). These results to a statistically significant extent lent support to the efficacy and optimal dose of CoQ10 supplementation on attenuating oxidative stress status in adults.

20 September 2022 in Advances in Nutrition
Verified
Journal Article
Open access
PDF file
DZDan Zhao
Dan Zhao
YLYing Liang
Ying Liang
SDSuming Dai
Suming Dai
SHShanshan Hou
Shanshan Hou
ZLZhihao Liu
Zhihao Liu
YYYan Yang
Yan Yang
Previous studies have shown beneficial effects of Coenzyme Q10 (CoQ10) supplementation on blood pressure (BP). However, the optimal intake of CoQ10 on BP in patients with cardiometabolic disorders is unknown, and its effect on circulating CoQ10 is also unclear. We aimed to assess the dose-response relationship between CoQ10 and BP, and quantify the effect of CoQ10 supplementation on the level of circulating CoQ10 by synthesizing available evidence from randomized controlled trials (RCTs). A comprehensive literature search was performed in 3 databases (PubMed, Embase and Cochrane Library) up to 21st March 2022. A novel 1-stage restricted cubic spline regression model was used to evaluate the nonlinear dose-response relation between CoQ10 and BP. Twenty-six studies comprising 1831 subjects were included in our meta-analysis. CoQ10 supplementation significantly reduced SBP (-4.77 mmHg, 95% CI: -6.57, -2.97) in patients with cardiometabolic diseases; this reduction was accompanied by a 1.62 (95% CI: 1.26, 1.97) µg/ml elevation of circulating CoQ10 compared with the control group. Subgroup analyses revealed that the effects of reducing SBP were more pronounced in patients with diabetes and dyslipidemia and in studies with longer durations (>12 weeks). Importantly, a U-shaped dose-response relationship was observed between CoQ10 supplementation and SBP level, with an approximate a dose of 100-200 mg/d largely reducing SBP (χ2 = 10.84, Pnonlinearity = 0.004). The quality of evidence was rated as moderate, low, and very low for SBP, DBP, and circulating CoQ10 according to the Grading of Recommendations, Assessment, Development, and Evaluation approach (GRADE), respectively. The current finding demonstrated that the clinically beneficial effects of CoQ10 supplementation may be attributed to the reduction in SBP, and a 100–200mg/d of CoQ10 supplementation may achieve the greatest benefit on SBP in patients with cardiometabolic diseases. This study was registered on PROSPERO as CRD42021252933.

26 October 2019 in Food & Function
Verified
Journal Article
Closed access
PDF file
FYFuli Ya
Fuli Ya
XXXiaohong Ruby Xu
Xiaohong Ruby Xu
ZTZezhong Tian
Zezhong Tian
RGReid C. Gallant
Reid C. Gallant
FSFenglin Song
Fenglin Song
YYYan Yang
Yan Yang
CoQ10 supplementation in ApoE−/− mice attenuates high-fat diet-induced platelet hyper-reactivity via down-regulating platelet αIIbβ3 signaling, and thus protecting against atherothrombosis.

Verified
Journal Article
Open access
PDF file
RWRuijie Wang
Ruijie Wang
YCYiting Chen
Yiting Chen
ZTZezhong Tian
Zezhong Tian
MZMeiyan Zhu
Meiyan Zhu
BZBingying Zhang
Bingying Zhang
YYYan Yang
Yan Yang
Platelet hyperreactivity and oxidative stress are the important causes of thrombotic disorders in patients with COVID-19. Oxidative stress, induced by the excessive generation of reactive oxygen species (ROS), could increase platelet function and the risk of thrombus formation. Coenzyme Q10 (CoQ10), exhibits strong antioxidative activity and anti-platelet effect. However, the effects and mechanisms of CoQ10 on attenuating platelet aggregation induced by spike protein have never been studied. This study aims to investigate whether the SARS-CoV-2 spike protein potentiates human platelet function via ROS signaling and the protective effect of CoQ10 in vitro. Using a series of platelet function assays, we found that spike protein potentiated platelet aggregation and oxidative stress, such as ROS level, mitochondrial membrane potential depolarization, and lipid damage level (MDA and 8-iso-PGF2α) in vitro. Furthermore, CoQ10 attenuated platelet aggregation induced by spike protein. As an anti-platelet mechanism, we showed that CoQ10 significantly decreased the excess production of ROS induced by spike protein. Our findings show that the protective effect of CoQ10 on spike protein-potentiated platelet aggregation is probably associated with its strong antioxidative ability.

Verified
Journal Article
Open access
PDF file
YMYu-Heng Mao
Yu-Heng Mao
FSFenglin Song
Fenglin Song
YXYi-Xuan Xu
Yi-Xuan Xu
ASAng-Xin Song
Ang-Xin Song
ZWZhao-Mei Wang
Zhao-Mei Wang
YYYan Yang
Yan Yang
Cardiovascular diseases are associated with platelet hyperactivity, and downregulating platelet activation is one of the promising antithrombotic strategies. This study newly extracted two polysaccharides (purified exopolysaccharides, EPSp and purified intercellular exopolysaccharides, IPSp) from Cordyceps sinensis Cs-4 mycelial fermentation powder, and investigated the effects of the two polysaccharides and their gut bacterial metabolites on platelet functions and thrombus formation. EPSp and IPSp are majorly composed of galactose, mannose, glucose, and arabinose. Both EPSp and IPSp mainly contain 4-Galp and 4-Glcp glycosidic linkages. EPSp and IPSp significantly inhibited human platelet activation and aggregation with a dose-dependent manner, and attenuated thrombus formation in mice without increasing bleeding risk. Furthermore, the EPSp and IPSp after fecal fermentation showed enhanced platelet inhibitory effects. The results have demonstrated the potential value of Cs-4 polysaccharides as novel protective ingredients for cardiovascular diseases.